Martek Biosciences To Be Acquired By Royal DSM For $31.50/Share Cash (MATK)

In a deal 35% above Martek Biosciences MATK closing price yesterday, MATK is being acquired by Royal DSM for $31.50/share. The total deal will be worth $1.087 billion.